Venetoclax

Generic Name
Venetoclax
Brand Names
Venclexta, Venclyxto
Drug Type
Small Molecule
Chemical Formula
C45H50ClN7O7S
CAS Number
1257044-40-8
Unique Ingredient Identifier
N54AIC43PW
Background

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .

Indication

本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。

Associated Conditions
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Associated Therapies
-
Clinical Trials
Related News

Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia

First Posted Date
2018-08-16
Last Posted Date
2023-06-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
16
Registration Number
NCT03634228
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

First Posted Date
2018-08-14
Last Posted Date
2024-11-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
52
Registration Number
NCT03629171
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

First Posted Date
2018-08-10
Last Posted Date
2021-09-14
Lead Sponsor
AbbVie
Target Recruit Count
61
Registration Number
NCT03625505
Locations
🇺🇸

Northwestern Memorial Hospital /ID# 200230, Chicago, Illinois, United States

🇺🇸

Sylvester Comprehensive Cancer /ID# 200268, Miami, Florida, United States

🇺🇸

David Geffen School of Medicin /ID# 200166, Los Angeles, California, United States

and more 8 locations

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

First Posted Date
2018-08-03
Last Posted Date
2024-01-26
Lead Sponsor
Jacqueline Garcia, MD
Target Recruit Count
100
Registration Number
NCT03613532
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

Phase 2
Active, not recruiting
Conditions
Chronic Lymphocytic Leukemia
Interventions
Drug: Bendamustine
Drug: Venetoclax
Drug: Rituximab
First Posted Date
2018-08-01
Last Posted Date
2024-04-02
Lead Sponsor
Nicole Lamanna
Target Recruit Count
42
Registration Number
NCT03609593
Locations
🇺🇸

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York, United States

Expanded Access to Navitoclax

First Posted Date
2018-07-19
Last Posted Date
2024-05-06
Lead Sponsor
AbbVie
Registration Number
NCT03592576

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

First Posted Date
2018-07-13
Last Posted Date
2024-11-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
145
Registration Number
NCT03586609
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

First Posted Date
2018-07-12
Last Posted Date
2022-06-28
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
103
Registration Number
NCT03584009
Locations
🇺🇸

University of Maryland Medical Center, Baltimore, Maryland, United States

🇺🇸

Nebraska Hematology Onco, PC, Lincoln, Nebraska, United States

🇦🇺

Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research, North Sydney, New South Wales, Australia

and more 37 locations

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

First Posted Date
2018-07-11
Last Posted Date
2021-10-06
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
19
Registration Number
NCT03583424
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

First Posted Date
2018-07-10
Last Posted Date
2024-07-30
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
72
Registration Number
NCT03580928
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut, United States

🇺🇸

Lifespan Cancer Institute, Providence, Rhode Island, United States

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy